Health Care • Medical Specialities
$2.04 ▼ -0.02
(-0.97%)
MKT CAP: $81.3M • VOL: 86.0K
52W L $2 52W H $4
SERA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $81.0K | $77.0K | $306.0K |
| YoY Revenue Growth % | +5.2% | -74.8% | — |
| Gross Profit | -$83.0K | -$5.0K | — |
| Gross Margin % | -50.0% | -6.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.5M | -$36.6M | -$39.8M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$31.9M | -$32.9M | -$36.2M |
| EBITDA (Normalized) | -$35.9M | -$36.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.6M | -$14.2M | -$27.2M |
| Capital Expenditures (CapEx) | $726.0K | $56.0K | — |
| Free Cash Flow (FCF) | -$26.3M | -$14.2M | -$27.2M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -40.4% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.9M | $4.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $75.4M | $47.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SERA.